Advertisement

Drug Exposure and Intrauterine Growth

  • Sabrina D. Diaz
  • Lynne M. Smith
Chapter

Abstract

The effects of prenatal drug exposure on intrauterine growth restriction are widely acknowledged. Prevalence rates of drug-abusing women who are of reproductive age are of concern worldwide. This chapter summarizes what is known regarding the impact of prenatal exposure to various illicit and legal drugs on intrauterine growth. Brief descriptions of the drugs and the mechanisms which impact growth are also discussed. Decreased birth weight, height and head circumference, as well as increased incidence of prematurity and small for gestational age are common findings in infants who were prenatally exposed to cocaine, methamphetamines, opiates, methadone, buprenorphine, marijuana, alcohol, and nicotine. However, the studies reviewed vary in sample size and characteristics, measures used to confirm drug use, study design, and whether or not they control for potential confounders. A major design flaw in many studies is the lack of control for polydrug use. Though some studies have found no effects of prenatal drug exposure, these results should not diminish the importance of educating females regarding the potentially harmful effects of drug use during pregnancy and for continued efforts to identify optimal treatment therapies for drug-dependent pregnant and parenting women.

Keywords

Head Circumference Growth Effect Intrauterine Growth Restriction Prenatal Alcohol Exposure Fetal Hypoxia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

LSD

Lysergic acid diethylamide

MDMA

3,4-Methylenedioxymethamphetamine

PCP

Phencyclidine

SES

Socioeconomic status

THC

Delta-9-tetrahydrocannabinol

Notes

Acknowledgments

Due to space constraints it was not possible to cite all reports regarding prenatal drug exposure. We sincerely thank all contributors to this discipline who have not been mentioned in this chapter. The authors thank Vincent Lucky Gamache, Jr. for his valuable contribution to Fig. 15.1.

References

  1. Arria AM, Derauf C, LaGasse LL, Grant P, Shah R, Smith L, Haning W, Huestis M, Strauss A, Della GS, Liu J, Lester B. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern. Child Health J. 2006;10:293–302.Google Scholar
  2. Ashwal S, Michelson D, Plawner L, Dobyns WB. Practice parameter: evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2009;73:887–97.PubMedCrossRefGoogle Scholar
  3. Bada HS, Das A, Bauer CR, Shankaran S, Lester B, Wright LL, Verter J, Smeriglio VL, Finnegan LP, Maza PL. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet. Gynecol. 2002;100:916–24.PubMedCrossRefGoogle Scholar
  4. Bandstra ES, Morrow CE, Anthony JC, Churchill SS, Chitwood DC, Steele BW, Ofir AY, Xue L. Intrauterine growth of full-term infants: impact of prenatal cocaine exposure. Pediatrics 2001;108:1309–19.PubMedCrossRefGoogle Scholar
  5. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993;306:422–6.PubMedCrossRefGoogle Scholar
  6. Barr HM, Streissguth AP. Caffeine use during pregnancy and child outcome: a 7-year prospective study. Neurotoxicol Teratol. 1991;13:441–8.PubMedCrossRefGoogle Scholar
  7. Barr HM, Streissguth AP, Martin DC, Herman CS. Infant size at 8 months of age: relationship to maternal use of alcohol, nicotine, and caffeine during pregnancy. Pediatrics 1984;74:336–41.PubMedGoogle Scholar
  8. Bateman DA, Chiriboga CA. Dose-response effect of cocaine on newborn head circumference. Pediatrics 2000;106(E33):1–6.CrossRefGoogle Scholar
  9. Blumenthal S, Bergner L, Nelson F. Low birth weight of infants associated with maternal heroin use: New York City, 1966–67 and 1970–71. Health Serv Rep 1973;88:416–8.PubMedCrossRefGoogle Scholar
  10. Bracken MB, Triche EW, Belanger K, Hellenbrand K, Leaderer BP. Association of maternal caffeine consumption with decrements in fetal growth. Am J Epidemiol 2003;157:456–466.PubMedCrossRefGoogle Scholar
  11. Bureau of International Narcotics and Law Enforcement Affairs. International narcotics control strategy report. Volume 1: Drug and chemical control. Washington, DC; 2009.Google Scholar
  12. Caan BJ, Goldhaber MK. Caffeinated beverages and low birthweight: a case-control study. Am J Public Health 1989;79:1299–300.PubMedCrossRefGoogle Scholar
  13. Carter RC, Jacobson SW, Molteno CD, Jacobson JL. Fetal alcohol exposure, iron-deficiency anemia, and infant growth. Pediatrics 2007;120:559–67.PubMedCrossRefGoogle Scholar
  14. CDC. Alcohol use among pregnant and nonpregnant women of childbearing age – United States, 1991–2005. MMWR Morb Mortal Wkly Rep 2009;58(19):529–32.Google Scholar
  15. Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterstrom R. Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr. 1996;85:204–8.PubMedCrossRefGoogle Scholar
  16. Chasnoff IJ, Burns KA, Burns WJ, Schnoll SH. Prenatal drug exposure: effects on neonatal and infant growth and development. Neurobehav Toxicol Teratol 1986;8:357–362.PubMedGoogle Scholar
  17. Chasnoff IJ, Griffith DR, MacGregor S, Dirkes K, Burns KA. Temporal patterns of cocaine use in pregnancy. Perinatal outcome. JAMA 1989;261:1741–4.PubMedCrossRefGoogle Scholar
  18. Chiriboga CA, Brust JC, Bateman D, Hauser WA. Dose-response effect of fetal cocaine exposure on newborn neurologic function. Pediatrics 1999;103:79–85.PubMedCrossRefGoogle Scholar
  19. Coleman T. Reducing harm from tobacco smoke exposure during pregnancy. Birth Defects Res C Embryo Today 2008;1:73–9.CrossRefGoogle Scholar
  20. Coles CD, Brown RT, Smith IE, Platzman KA, Erickson S, Falek A. Effects of prenatal alcohol exposure at school age. I. Physical and cognitive development. Neurotoxicol Teratol 1991;13:357–67.PubMedCrossRefGoogle Scholar
  21. Cornelius MD, Taylor PM, Geva D, Day NL. Alcohol, tobacco and marijuana use among pregnant teenagers: 6-year follow-up of offspring growth effects. Pediatrics 1995;95:738–43.PubMedGoogle Scholar
  22. Cornelius MD, Goldshmidt L, Taylor PM, Day NL. Prenatal alcohol use among teenagers: effects on neonatal outcomes. Alcohol Clin Exp Res 1999;23:1238–44.PubMedCrossRefGoogle Scholar
  23. Cornelius MD, Goldschmidt L, Day NL, Larkby C. Prenatal tobacco and marijuana use among adolescents: effects on offspring gestational age, growth, and morphology. Neurotoxicol Teratol 2002;24:703–10.PubMedCrossRefGoogle Scholar
  24. Day N, Cornelius M, Goldschmidt L, Richardson G, Robles N, Taylor P. The effects of prenatal tobacco and marijuana use on offspring growth from birth through 3 years of age. Neurotoxicol Teratol 1991a;15:67–71.Google Scholar
  25. Day N, Sambamoorthi U, Taylor P, Richardson G, Robles N, Jhon Y, Scher M, Stoffer D, Cornelius M, Jasperse D. Prenatal marijuana use and neonatal outcome. Neurotoxicol Teratol 1991b;13:329–34.PubMedCrossRefGoogle Scholar
  26. Day NL, Robles N, Richardson G, Geva D, Taylor P, Scher M, Stoffer D, Cornelius M, Goldschmidt L. Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. Alcohol Clin Exp Res 1991c;15:67–71.PubMedCrossRefGoogle Scholar
  27. Day NL, Richardson GA, Geva D, Robles N. The effects of prenatal alcohol use on the growth of children at three years of age. Alcohol Clin Exp Res 1994;18:786–94.PubMedCrossRefGoogle Scholar
  28. Day NL, Zuo Y, Richardson GA, Goldschmidt L, Larkby CA, Cornelius MD. Prenatal alcohol use and offspring size at 10 years of age. Alcohol Clin Exp Res 1999;23:863–9.PubMedCrossRefGoogle Scholar
  29. Delpisheh A, Topping J, Reyad M, Tang A, Brabin BJ. Prenatal alcohol exposure, CYP17 gene polymorphisms and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2008;138:49–53.PubMedCrossRefGoogle Scholar
  30. England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003;189:939–43.PubMedCrossRefGoogle Scholar
  31. Eriksson M, Zetterstrom R. Amphetamine addiction during pregnancy: 10-year follow-up. Acta Paediatr Suppl 1994;404:27–31.PubMedCrossRefGoogle Scholar
  32. Ernhart CB, Wolf AW, Linn PL, Sokol RJ, Kennard MJ, Filipovich HF. Alcohol-related birth defects: syndromal anomalies, intrauterine growth retardation, and neonatal behavioral assessment. Alcohol Clin Exp Res 1985;9:447–53.PubMedCrossRefGoogle Scholar
  33. Eskenazi B, Bergmann JJ. Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. I. Effects on physical growth at age 5 years. Am J Epidemiol 1995;142:S10–S8.CrossRefGoogle Scholar
  34. European Monitoring Centre for Drugs and Drug Addiction, EMCDDA. Statistical bulletin. Lisbon; 2009.Google Scholar
  35. Eyler FD, Behnke M, Conlon M, Woods NS, Wobie K. Birth outcome from a prospective, matched study of prenatal crack/cocaine use: I. Interactive and dose effects on health and growth. Pediatrics 1998;101:229–37.PubMedCrossRefGoogle Scholar
  36. Fenster L, Eskenazi B, Windham GC, Swan SH. Caffeine consumption during pregnancy and fetal growth. Am J Public Health 1991;81:458–61.PubMedCrossRefGoogle Scholar
  37. Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. BJOG 2002;109:21–7.PubMedCrossRefGoogle Scholar
  38. Fogelman KR, Manor O. Smoking in pregnancy and development into early adulthood. BMJ 1988;297:1233–6.PubMedCrossRefGoogle Scholar
  39. Fox NL, Sexton M, Hebel JR. Prenatal exposure to tobacco: I. Effects on physical growth at age three. Int J Epidemiol 1990;19:66–71.PubMedCrossRefGoogle Scholar
  40. Frank DA, Bresnahan K, Zuckerman BS. Maternal cocaine use: impact on child health and development. Curr Probl Pediatr 1996;26:57–70.PubMedCrossRefGoogle Scholar
  41. Fried PA, O’Connell CM. Growth and pubertal milestones during adolescence in offspring prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1987;9:79–85.PubMedCrossRefGoogle Scholar
  42. Fried PA, Watkinson B, Gray R. A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. Neurotoxicol Teratol 1999;21:513–25.PubMedCrossRefGoogle Scholar
  43. Fried PA, James DS, Watkinson B. Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 2001;23:431–6.PubMedCrossRefGoogle Scholar
  44. Godel JC, Pabst HF, Hodges PE, Johnson KE, Froese GJ, Joffres MR. Smoking and caffeine and alcohol intake during pregnancy in a northern population: effect on fetal growth. CMAJ 1992;147:181–8.Google Scholar
  45. Greene T, Ernhart CB, Sokol RJ, Martier S, Marler MR, Boyd TA, Ager J. Prenatal alcohol exposure and preschool physical growth: a longitudinal analysis. Alcohol Clin Exp Res 1991;15:905–13.PubMedCrossRefGoogle Scholar
  46. Hadeed AJ, Siegel SR. Maternal cocaine use during pregnancy: effect on the newborn infant. Pediatrics 1989;84:205–10.PubMedGoogle Scholar
  47. Hatch EE, Bracken MB. Effect of marijuana use in pregnancy on fetal growth. Am J Epidemiol 1986;124:986–93.PubMedGoogle Scholar
  48. Hingson R, Alpert JJ, Day N, Dooling E, Kayne H, Morelock S, Oppenheimer E, Zuckerman B. Effects of maternal drinking and marijuana use on fetal growth and development. Pediatrics 1982;70:539–46.PubMedGoogle Scholar
  49. Jacobson JL, Jacobson SW, Sokol RJ. Effects of prenatal exposure to alcohol, smoking, and illicit drugs on postpartum somatic growth. Alcohol Clin Exp Res. 1994;18:317–23.PubMedCrossRefGoogle Scholar
  50. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973;302:999–1001.PubMedCrossRefGoogle Scholar
  51. Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007;86:185–90.PubMedCrossRefGoogle Scholar
  52. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69–78.PubMedCrossRefGoogle Scholar
  53. Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. Neurotoxicol Teratol 1987;9:311–3.PubMedCrossRefGoogle Scholar
  54. Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. The narcotic-dependent mother: fetal and neonatal consequences. Pediatrics 1976;58:681–5.PubMedGoogle Scholar
  55. Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. Differential effects of maternal heroin and methadone use on birthweight. Early Hum Dev 1977;1:159–69.PubMedCrossRefGoogle Scholar
  56. Kullander S, Källén B. A prospective study of smoking and pregnancy. Acta Obstet Gynecol Scand 1971;50:83–94.CrossRefGoogle Scholar
  57. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99:209–14.PubMedCrossRefGoogle Scholar
  58. Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol. 1992;32:216–21.PubMedCrossRefGoogle Scholar
  59. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82:250–7.PubMedCrossRefGoogle Scholar
  60. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. J Pediatr 1983;102:686–91.PubMedCrossRefGoogle Scholar
  61. Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985;75:269–74.PubMedGoogle Scholar
  62. Lindley AA, Becker S, Gray RH, Herman AA. Effect of continuing or stopping smoking during pregnancy on infant birth weight, crown-heel length, head circumference, ponderal index, and brain:body weight ratio. Am J Epidemiol 2000;152:219–25.PubMedCrossRefGoogle Scholar
  63. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. No association between coffee consumption and adverse outcomes of pregnancy. N Engl J Med 1982;306:141–5.PubMedCrossRefGoogle Scholar
  64. Little RE. Methamphetamine abuse during pregnancy: outcome and fetal effects. Am J Public Health 1977;67:1154–6.PubMedCrossRefGoogle Scholar
  65. Little RE, Asker RL, Sampson PD, Renwick JH. Moderate alcohol use during pregnancy and decreased infant birth weight. Am J Epidemiol. 1986;123:270–8.PubMedGoogle Scholar
  66. Little BB, Snell LM, Gilstrap LC, III. Fetal growth and moderate drinking in early pregnancy. Obstet Gynecol 1988;72:541–4.PubMedGoogle Scholar
  67. Mainous AG, III, Hueston WJ. Passive smoke and low birth weight. Evidence of a threshold effect. Arch Fam Med 1994;3:875–8.PubMedCrossRefGoogle Scholar
  68. Martin TR, Bracken MB. Association of low birth weight with passive smoke exposure in pregnancy. Am J Epidemiol. 1986;124:633–42.PubMedGoogle Scholar
  69. Martin TR, Bracken MB. The association between low birth weight and caffeine consumption during pregnancy. Am J Epidemiol 1987;126:813–21.PubMedGoogle Scholar
  70. McDonald AD, Armstrong BG, Sloan M. Cigarette, alcohol, and coffee consumption and prematurity. Am J Public Health 1992;82:87–90.PubMedCrossRefGoogle Scholar
  71. Mills JL, Holmes LB, Aarons JH, Simpson JL, Brown ZA, Jovanovic-Peterson LG, Conley MR, Graubard BI, Knopp RH, Metzger BE. Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA 1993;269:593–7.PubMedCrossRefGoogle Scholar
  72. Naeye RL, Blanc W, Leblanc W, Khatamee MA. Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. J Pediatr 1973;83:1055–61.PubMedCrossRefGoogle Scholar
  73. Nordstrom-Klee B, Delaney-Black V, Covington C, Ager J, Sokol R. Growth from birth onwards of children prenatally exposed to drugs: a literature review. Neurotoxicol Teratol. 2002;24:481–8.PubMedCrossRefGoogle Scholar
  74. Ornoy A, Michailevskaya V, Lukashov I, Bar-Hamburger R, Harel S. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl 1996;20:385–96.PubMedCrossRefGoogle Scholar
  75. Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr 1987;111:571–8.PubMedCrossRefGoogle Scholar
  76. Quinlivan JA, Evans SF. The impact of continuing illegal drug use on teenage pregnancy outcomes – a prospective cohort study. BJOG. 2002;109:1148–53.PubMedGoogle Scholar
  77. Rahbar F, Fomufod A, White D, Westney LS. Impact of intrauterine exposure to phencyclidine (PCP) and cocaine on neonates. J Natl Med Assoc 1993;85:349–52.PubMedGoogle Scholar
  78. Richardson GA, Hamel SC, Goldschmidt L, Day NL. Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample. Pediatrics 1999;104(e18):1–10.CrossRefGoogle Scholar
  79. Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-up to 18 months of age. J Pediatr 1982;101:192–6.PubMedCrossRefGoogle Scholar
  80. Shankaran S, Das A, Bauer CR, Bada H, Lester B, Wright L, Higgins R, Poole K. Fetal origin of childhood disease: intrauterine growth restriction in term infants and risk for hypertension at 6 years of age. Arch Pediatr Adolesc Med 2006;160:977–81.PubMedCrossRefGoogle Scholar
  81. Shiono PH, Klebanoff MA, Nugent RP, Cotch MF, Wilkins DG, Rollins DE, Carey JC, Behrman RE. The impact of cocaine and marijuana use on low birth weight and preterm birth: a multicenter study. Am J Obstet Gynecol. 1995;172:19–27.PubMedCrossRefGoogle Scholar
  82. Shu XO, Hatch MC, Mills J, Clemens J, Susser M. Maternal smoking, alcohol drinking, caffeine consumption, and fetal growth: results from a prospective study. Epidemiology 1995;6:115–20.PubMedCrossRefGoogle Scholar
  83. Smith L, Yonekura ML, Wallace T, Berman N, Kuo J, Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 2003;24:17–23.PubMedCrossRefGoogle Scholar
  84. Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della GS, Liu J, Lester BM. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006;118:1149–56.PubMedCrossRefGoogle Scholar
  85. Strauss AA, Modaniou HD, Bosu SK. Neonatal manifestations of maternal phencyclidine (PCP) abuse. Pediatrics. 1981;68:550–2.PubMedGoogle Scholar
  86. Streissguth AP, Aase JM, Clarren SK, Randels SP, LaDue RA, Smith DF. Fetal alcohol syndrome in adolescents and adults. JAMA. 1991;265:1961–7.PubMedCrossRefGoogle Scholar
  87. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings. (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD; 2008.Google Scholar
  88. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: National Findings. (NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD; 2009a.Google Scholar
  89. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) Highlights – 2007. National Admissions to Substance Abuse Treatment Services. (DASIS Series: S-45, DHHS Publication No. SMA 09-4360). Rockville, MD; 2009b.Google Scholar
  90. Tabor BL, Smith-Wallace T, Yonekura ML. Perinatal outcome associated with PCP versus cocaine use. Am J Drug Alcohol Abuse. 1990;16:337–48.PubMedCrossRefGoogle Scholar
  91. Tejani Z, LaGasse LL, Derauf C, Newman E, Shah R, Smith L, Arria A, Huestis M, DellaGrotta S, Liu J, Lester BM. Prenatal methamphetamine (MA) exposure and growth at 12, 24, and 36 months: preliminary results from the Infant Development, Environment, and Lifestyle (IDEAL) study. J Investig Med. 2008;56:142.Google Scholar
  92. Tennes K, Avitable N, Blackard C, Boyles C, Hassoun B, Holmes L, Kreye M. Marijuana: prenatal and postnatal exposure in the human. NIDA Res Monogr. 1985;59:48–60.PubMedGoogle Scholar
  93. The NHS Information Centre, Lifestyle Statistics. Statistics on alcohol: England. 2009. The Health and Social Care Information Centre, United Kingdom; 2009.Google Scholar
  94. Visscher WA, Feder M, Burns AM, Brady TM, Bray RM. The impact of smoking and other substance use by urban women on the birthweight of their infants. Subst Use Misuse. 2003;38:1063–93.PubMedCrossRefGoogle Scholar
  95. Weinberg B, Bealer B. The world of caffeine. The science and culture of the world’s most popular drug. London: Routledge; 2001.Google Scholar
  96. Wilson GS, Desmond MM, Verniaud WM. Early development of infants of heroin-addicted mothers. Am J Dis Child. 1973;126:457–62.PubMedGoogle Scholar
  97. Wilson GS, McCreary R, Kean J, Baxter JC. The development of preschool children of heroin-addicted mothers: a controlled study. Pediatrics. 1979;63:135–41.PubMedGoogle Scholar
  98. Windham GC, Fenster L, Hopkins B, Swan SH. The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age. Epidemiology. 1995;6:591–7.PubMedCrossRefGoogle Scholar
  99. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, Parker S, Vinci R, Aboagye K, Fried LE. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med. 1989;320:762–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Los Angeles Biomedical Institute at Harbor-UCLA Medical CenterTorranceUSA
  2. 2.David Geffen School of Medicine, Harbor-UCLA Medical CenterTorranceUSA

Personalised recommendations